Sakari Simula
Overview
Explore the profile of Sakari Simula including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
231
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahvenjarvi H, Niiranen M, Simula S, Hamalainen P, Surcel H, Remes A, et al.
Mult Scler Relat Disord
. 2023 Jul;
77:104861.
PMID: 37442075
Background: Fatigue is a prominent and disabling symptom of multiple sclerosis (MS), impairing quality of life. The disease course of relapsing remitting MS (RRMS) is individual. Objectives: We aimed to...
2.
Niiranen M, Koikkalainen J, Lotjonen J, Selander T, Cajanus A, Hartikainen P, et al.
Brain Behav
. 2022 Jun;
12(7):e2679.
PMID: 35765699
Background: Brain atrophy appears during the progression of multiple sclerosis (MS) and is associated with the disability caused by the disease. Methods: We investigated global and regional grey matter (GM)...
3.
Niiranen M, Kontkanen A, Jaaskelainen O, Tertsunen H, Selander T, Hartikainen P, et al.
Mult Scler Relat Disord
. 2021 Oct;
56:103280.
PMID: 34627002
Objective: We aimed to investigate serum glial fibrillary acidic protein (GFAP) and serum neurofilament light chain (NfL) levels as potential discriminative biomarkers between benign relapsing-remitting multiple sclerosis (BRRMS) and aggressive...
4.
Rauma I, Mustonen T, Seppa J, Ukkonen M, Mannikko M, Verkkoniemi-Ahola A, et al.
J Neurol
. 2021 Jul;
269(2):824-835.
PMID: 34255182
Background: Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clinical practice. Objectives: To evaluate the safety of alemtuzumab...
5.
Mustonen T, Rauma I, Hartikainen P, Kruger J, Niiranen M, Selander T, et al.
Mult Scler Relat Disord
. 2020 Jun;
41:102107.
PMID: 32571611
No abstract available.
6.
Mustonen T, Rauma I, Hartikainen P, Kruger J, Niiranen M, Selander T, et al.
Mult Scler Relat Disord
. 2019 Dec;
38:101498.
PMID: 31864192
Background: Natalizumab (NTZ) is widely used for highly active relapsing-remitting multiple sclerosis (MS). Inflammatory disease activity often returns after NTZ treatment discontinuation. We aimed to identify predictive factors for such...
7.
Laiho A, Laitinen T, Hartikainen P, Hartikainen J, Laitinen T, Simula S
Brain Behav
. 2018 Feb;
8(2):e00925.
PMID: 29484274
Background: Fingolimod is a sphingosine-1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis (RRMS). Despite an established effect on heart rate, the effect of fingolimod on cardiac repolarization is...
8.
Mikkola A, Ojanen A, Hartikainen J, Remes A, Simula S
Mult Scler Relat Disord
. 2018 Feb;
20:205-209.
PMID: 29428463
Background: Cardiac repolarization is modulated by the autonomic nervous system. Even though multiple sclerosis associates with prolonged cardiac repolarization the physiology responsible for the phenomenon remains unknown. Objective: To study...
9.
Mikkola A, Ojanen A, Hartikainen J, Remes A, Simula S
Brain Behav
. 2017 Jul;
7(7):e00742.
PMID: 28729944
Introduction: Multiple sclerosis is associated with prolonged cardiac repolarization but the underlying physiology has remained unknown. In this study, we compared cardiac repolarization during the relapsing-remitting multiple sclerosis (RRMS) disease...
10.
Simula S, Laitinen T, Laitinen T, Hartikainen P, Hartikainen J
Ann Noninvasive Electrocardiol
. 2017 Feb;
22(5).
PMID: 28191684
Background: Homeostasis between heart rate and blood pressure is based on several interacting regulatory reflexes, which become influenced by fingolimod initiation. The aim of this study was to determine the...